<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35743272</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>19</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Optineurin Deficiency and Insufficiency Lead to Higher Microglial TDP-43 Protein Levels.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">6829</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23126829</ELocationID><Abstract><AbstractText>Mutations in optineurin, a ubiquitin-binding adaptor protein, cause amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease of motor neurons linked to chronic inflammation and protein aggregation. The majority of ALS patients, including those carrying the optineurin mutations, exhibit cytoplasmic mislocalization, ubiquitination, and aggregation of nuclear TAR DNA-binding protein 43 kDa (TDP-43). To address the crosstalk between optineurin and TDP-43, we generated optineurin knockout (KO) neuronal and microglial cell lines using the CRISPR/Cas9 approach. Interestingly, we observed that loss of optineurin resulted in elevated TDP-43 protein expression in microglial BV2 but not neuronal Neuro 2a and NSC-34 cell lines. No changes were observed at the mRNA level, suggesting that this increase was post-translationally regulated. To confirm this observation in primary cells, we then used microglia and macrophages from an optineurin loss-of-function mouse model that lacks the C-terminal ubiquitin-binding region (Optn<sup>470T</sup>), mimicking optineurin truncations in ALS patients. As observed in the BV2 cells, we also found elevated basal levels of TDP-43 protein in Optn<sup>470T</sup> microglia and bone marrow-derived macrophages. To test if inflammation could further enhance TDP-43 accumulation in cells lacking functional optineurin, we stimulated them with lipopolysaccharide (LPS), and we observed a significant increase in TDP-43 expression following LPS treatment of WT cells. However, this was absent in both BV2 Optn KO and primary Optn<sup>470T</sup> microglia, which exhibited the same elevated TDP-43 levels as in basal conditions. Furthermore, we did not observe nuclear TDP-43 depletion or cytoplasmic aggregate formation in either Optn<sup>470T</sup> microglia or LPS-treated WT or Optn<sup>470T</sup> microglia. Taken together, our results show that optineurin deficiency and insufficiency post-translationally upregulate microglial TDP-43 protein levels and that elevated TDP-43 levels in cells lacking functional optineurin could not be further increased by an inflammatory stimulus, suggesting the presence of a plateau.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prtenjaca</LastName><ForeName>Nikolina</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-7744-904X</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Immunology, Department of Biotechnology, University of Rijeka, R. Matejcic 2, 51000 Rijeka, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rob</LastName><ForeName>Matea</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Immunology, Department of Biotechnology, University of Rijeka, R. Matejcic 2, 51000 Rijeka, Croatia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Genetics, Dementia Research Institute, Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge CB2 0XY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alam</LastName><ForeName>Muhammad S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markovinovic</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1656-3150</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Immunology, Department of Biotechnology, University of Rijeka, R. Matejcic 2, 51000 Rijeka, Croatia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stuani</LastName><ForeName>Cristiana</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano 99, 34149 Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buratti</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-1356-9074</Identifier><AffiliationInfo><Affiliation>International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano 99, 34149 Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munitic</LastName><ForeName>Ivana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Immunology, Department of Biotechnology, University of Rijeka, R. Matejcic 2, 51000 Rijeka, Croatia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>IP-2018-01-8563</GrantID><Agency>Croatian Science Foundation</Agency><Country/></Grant><Grant><GrantID>18-211-1369</GrantID><Agency>University of Rijeka</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035582">Transcription Factor TFIIIA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014452">Ubiquitins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035582" MajorTopicYN="N">Transcription Factor TFIIIA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014452" MajorTopicYN="N">Ubiquitins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">autophagy</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">optineurin</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35743272</ArticleId><ArticleId IdType="pmc">PMC9224222</ArticleId><ArticleId IdType="doi">10.3390/ijms23126829</ArticleId><ArticleId IdType="pii">ijms23126829</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic Lateral Sclerosis. Nat. Rev. Dis. Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;land L.-C., Markovinovic A., Jakovac H., De Marchi F., Bilic E., Mazzini L., Kriz J., Munitic I. Immunity in Amyotrophic Lateral Sclerosis: Blurred Lines between Excessive Inflammation and Inefficient Immune Responses. Brain Commun. 2020;2:fcaa124. doi: 10.1093/braincomms/fcaa124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa124</ArticleId><ArticleId IdType="pmc">PMC7585698</ArticleId><ArticleId IdType="pubmed">33134918</ArticleId></ArticleIdList></Reference><Reference><Citation>Geloso M.C., Corvino V., Marchese E., Serrano A., Michetti F., D&#x2019;Ambrosi N. The Dual Role of Microglia in ALS: Mechanisms and Therapeutic Approaches. Front. Aging Neurosci. 2017;9:242. doi: 10.3389/fnagi.2017.00242.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00242</ArticleId><ArticleId IdType="pmc">PMC5524666</ArticleId><ArticleId IdType="pubmed">28790913</ArticleId></ArticleIdList></Reference><Reference><Citation>Noristani H.N., Sabourin J.C., Gerber Y.N., Teigell M., Sommacal A., dM Vivanco M., Weber M., Perrin F.E. Brca1 Is Expressed in Human Microglia and Is Dysregulated in Human and Animal Model of ALS. Mol. Neurodegener. 2015;10:34. doi: 10.1186/s13024-015-0023-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0023-x</ArticleId><ArticleId IdType="pmc">PMC4521418</ArticleId><ArticleId IdType="pubmed">26227626</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., et al. TDP-43 Is a Component of Ubiquitin-Positive Tau-Negative Inclusions in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R., Rademakers R. The Role of Transactive Response DNA-Binding Protein-43 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Curr. Opin. Neurol. 2008;21:693&#x2013;700. doi: 10.1097/WCO.0b013e3283168d1d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e3283168d1d</ArticleId><ArticleId IdType="pmc">PMC2869081</ArticleId><ArticleId IdType="pubmed">18989115</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A., Buratti E. Physiological Functions and Pathobiology of TDP-43 and FUS/TLS Proteins. J. Neurochem. 2016;138:95&#x2013;111. doi: 10.1111/jnc.13625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13625</ArticleId><ArticleId IdType="pubmed">27015757</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciryam P., Lambert-Smith I.A., Bean D.M., Freer R., Cid F., Tartaglia G.G., Saunders D.N., Wilson M.R., Oliver S.G., Morimoto R.I., et al. Spinal Motor Neuron Protein Supersaturation Patterns Are Associated with Inclusion Body Formation in ALS. Proc. Natl. Acad. Sci. USA. 2017;114:3935&#x2013;3943. doi: 10.1073/pnas.1613854114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1613854114</ArticleId><ArticleId IdType="pmc">PMC5441770</ArticleId><ArticleId IdType="pubmed">28396410</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B.S., Snead D., Lee J.J., McCaffery J.M., Shorter J., Gitler A.D. TDP-43 Is Intrinsically Aggregation-Prone, and Amyotrophic Lateral Sclerosis-Linked Mutations Accelerate Aggregation and Increase Toxicity. J. Biol. Chem. 2009;284:20329&#x2013;20339. doi: 10.1074/jbc.M109.010264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.010264</ArticleId><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A., Bharathi V., Sivalingam V., Girdhar A., Patel B.K. Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Front. Mol. Neurosci. 2019;12:25. doi: 10.3389/fnmol.2019.00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki W., Minegishi S., Motoki K., Kume H., Hohjoh H., Araki Y.M., Tamaoka A. Disease-Associated Mutations of TDP-43 Promote Turnover of the Protein Through the Proteasomal Pathway. Mol. Neurobiol. 2014;50:1049&#x2013;1058. doi: 10.1007/s12035-014-8644-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-8644-6</ArticleId><ArticleId IdType="pubmed">24477737</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter E.L., Vance C., Nishimura A.L., Lee Y.-B., Chen H.-J., Urwin H., Sardone V., Mitchell J.C., Rogelj B., Rubinsztein D.C., et al. Differential Roles of the Ubiquitin Proteasome System and Autophagy in the Clearance of Soluble and Aggregated TDP-43 Species. J. Cell Sci. 2014;127:1263&#x2013;1278. doi: 10.1242/jcs.140087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.140087</ArticleId><ArticleId IdType="pmc">PMC3953816</ArticleId><ArticleId IdType="pubmed">24424030</ArticleId></ArticleIdList></Reference><Reference><Citation>Aman Y., Schmauck-Medina T., Hansen M., Morimoto R.I., Simon A.K., Bjedov I., Palikaras K., Simonsen A., Johansen T., Tavernarakis N., et al. Autophagy in Healthy Aging and Disease. Nat. Aging. 2021;1:634&#x2013;650. doi: 10.1038/s43587-021-00098-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-021-00098-4</ArticleId><ArticleId IdType="pmc">PMC8659158</ArticleId><ArticleId IdType="pubmed">34901876</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V., Phaneuf D., Dupr&#xe9; N., Petri S., Strong M., Kriz J., Julien J.-P. Deregulation of TDP-43 in Amyotrophic Lateral Sclerosis Triggers Nuclear Factor &#x39a;B&#x2013;Mediated Pathogenic Pathways. J. Exp. Med. 2011;208:2429&#x2013;2447. doi: 10.1084/jem.20111313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111313</ArticleId><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Correia A.S., Patel P., Dutta K., Julien J.-P. Inflammation Induces TDP-43 Mislocalization and Aggregation. PLoS ONE. 2015;10:e0140248. doi: 10.1371/journal.pone.0140248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0140248</ArticleId><ArticleId IdType="pmc">PMC4596857</ArticleId><ArticleId IdType="pubmed">26444430</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H., Morino H., Ito H., Izumi Y., Kato H., Watanabe Y., Kinoshita Y., Kamada M., Nodera H., Suzuki H., et al. Mutations of Optineurin in Amyotrophic Lateral Sclerosis. Nature. 2010;465:223&#x2013;226. doi: 10.1038/nature08971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08971</ArticleId><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Markovinovic A., Cimbro R., Ljutic T., Kriz J., Rogelj B., Munitic I. Optineurin in Amyotrophic Lateral Sclerosis: Multifunctional Adaptor Protein at the Crossroads of Different Neuroprotective Mechanisms. Prog. Neurobiol. 2017;154:1&#x2013;20. doi: 10.1016/j.pneurobio.2017.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2017.04.005</ArticleId><ArticleId IdType="pubmed">28456633</ArticleId></ArticleIdList></Reference><Reference><Citation>Akutsu M., Dikic I., Bremm A. Ubiquitin Chain Diversity at a Glance. J. Cell Sci. 2016;129:875&#x2013;880. doi: 10.1242/jcs.183954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.183954</ArticleId><ArticleId IdType="pubmed">26906419</ArticleId></ArticleIdList></Reference><Reference><Citation>Laplantine E., Fontan E., Chiaravalli J., Lopez T., Lakisic G., V&#xe9;ron M., Agou F., Isra&#xeb;l A. NEMO Specifically Recognizes K63-Linked Poly-Ubiquitin Chains through a New Bipartite Ubiquitin-Binding Domain. EMBO J. 2009;28:2885&#x2013;2895. doi: 10.1038/emboj.2009.241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2009.241</ArticleId><ArticleId IdType="pmc">PMC2760117</ArticleId><ArticleId IdType="pubmed">19763089</ArticleId></ArticleIdList></Reference><Reference><Citation>Markovinovic A., Ljutic T., B&#xe9;land L.-C., Munitic I. Optineurin Insufficiency Disbalances Proinflammatory and Anti-Inflammatory Factors by Reducing Microglial IFN-&#x3b2; Responses. Neuroscience. 2018;388:139&#x2013;151. doi: 10.1016/j.neuroscience.2018.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2018.07.007</ArticleId><ArticleId IdType="pubmed">30017954</ArticleId></ArticleIdList></Reference><Reference><Citation>Munitic I., Giardino Torchia M.L., Meena N.P., Zhu G., Li C.C., Ashwell J.D. Optineurin Insufficiency Impairs IRF3 but Not NF-&#x39a;B Activation in Immune Cells. J. Immunol. 2013;191:6231&#x2013;6240. doi: 10.4049/jimmunol.1301696.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1301696</ArticleId><ArticleId IdType="pmc">PMC3886234</ArticleId><ArticleId IdType="pubmed">24244017</ArticleId></ArticleIdList></Reference><Reference><Citation>Slowicka K., Vereecke L., Mc Guire C., Sze M., Maelfait J., Kolpe A., Saelens X., Beyaert R., van Loo G. Optineurin Deficiency in Mice Is Associated with Increased Sensitivity to Salmonella but Does Not Affect Proinflammatory NF-&#x39a;B Signaling. Eur. J. Immunol. 2016;46:971&#x2013;980. doi: 10.1002/eji.201545863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201545863</ArticleId><ArticleId IdType="pubmed">26677802</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleason C.E., Ordureau A., Gourlay R., Arthur J.S.C., Cohen P. Polyubiquitin Binding to Optineurin Is Required for Optimal Activation of TANK-Binding Kinase 1 and Production of Interferon &#x3b2;. J. Biol. Chem. 2011;286:35663&#x2013;35674. doi: 10.1074/jbc.M111.267567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.267567</ArticleId><ArticleId IdType="pmc">PMC3195586</ArticleId><ArticleId IdType="pubmed">21862579</ArticleId></ArticleIdList></Reference><Reference><Citation>Meena N.P., Zhu G., Mittelstadt P.R., Giardino Torchia M.L., Pourcelot M., Arnoult D., Ashwell J.D., Munitic I. The TBK1-Binding Domain of Optineurin Promotes Type I Interferon Responses. FEBS Lett. 2016;590:1498&#x2013;1508. doi: 10.1002/1873-3468.12176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.12176</ArticleId><ArticleId IdType="pmc">PMC4879041</ArticleId><ArticleId IdType="pubmed">27086836</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourcelot M., Zemirli N., Silva Da Costa L., Loyant R., Garcin D., Vitour D., Munitic I., Vazquez A., Arnoult D. The Golgi Apparatus Acts as a Platform for TBK1 Activation after Viral RNA Sensing. BMC Biol. 2016;14:69. doi: 10.1186/s12915-016-0292-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12915-016-0292-z</ArticleId><ArticleId IdType="pmc">PMC4991008</ArticleId><ArticleId IdType="pubmed">27538435</ArticleId></ArticleIdList></Reference><Reference><Citation>Korac J., Schaeffer V., Kovacevic I., Clement A.M., Jungblut B., Behl C., Terzic J., Dikic I. Ubiquitin-Independent Function of Optineurin in Autophagic Clearance of Protein Aggregates. J. Cell Sci. 2012;126:580&#x2013;592. doi: 10.1242/jcs.114926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.114926</ArticleId><ArticleId IdType="pmc">PMC3654196</ArticleId><ArticleId IdType="pubmed">23178947</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarou M., Sliter D.A., Kane L.A., Sarraf S.A., Wang C., Burman J.L., Sideris D.P., Fogel A.I., Youle R.J. The Ubiquitin Kinase PINK1 Recruits Autophagy Receptors to Induce Mitophagy. Nature. 2015;524:309&#x2013;314. doi: 10.1038/nature14893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14893</ArticleId><ArticleId IdType="pmc">PMC5018156</ArticleId><ArticleId IdType="pubmed">26266977</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild P., Farhan H., McEwan D.G., Wagner S., Rogov V.V., Brady N.R., Richter B., Korac J., Waidmann O., Choudhary C., et al. Phosphorylation of the Autophagy Receptor Optineurin Restricts Salmonella Growth. Science. 2011;333:228&#x2013;233. doi: 10.1126/science.1205405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1205405</ArticleId><ArticleId IdType="pmc">PMC3714538</ArticleId><ArticleId IdType="pubmed">21617041</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumbarello D.A., Waxse B.J., Arden S.D., Bright N.A., Kendrick-Jones J., Buss F. Autophagy Receptors Link Myosin VI to Autophagosomes to Mediate Tom1-Dependent Autophagosome Maturation and Fusion with the Lysosome. Nat. Cell Biol. 2012;14:1024&#x2013;1035. doi: 10.1038/ncb2589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb2589</ArticleId><ArticleId IdType="pmc">PMC3472162</ArticleId><ArticleId IdType="pubmed">23023224</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H., Nakamura M., Komure O., Ayaki T., Wate R., Maruyama H., Nakamura Y., Fujita K., Kaneko S., Okamoto Y., et al. Clinicopathologic Study on an ALS Family with a Heterozygous E478G Optineurin Mutation. Acta Neuropathol. 2011;122:223&#x2013;229. doi: 10.1007/s00401-011-0842-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0842-y</ArticleId><ArticleId IdType="pubmed">21644038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamada M., Izumi Y., Ayaki T., Nakamura M., Kagawa S., Kudo E., Sako W., Maruyama H., Nishida Y., Kawakami H., et al. Clinicopathologic Features of Autosomal Recessive Amyotrophic Lateral Sclerosis Associated with Optineurin Mutation: Autosomal Recessive OPTN-ALS. Neuropathology. 2014;34:64&#x2013;70. doi: 10.1111/neup.12051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12051</ArticleId><ArticleId IdType="pubmed">23889540</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurashige T., Kuramochi M., Ohsawa R., Yamashita Y., Shioi G., Morino H., Kamada M., Ayaki T., Ito H., Sotomaru Y., et al. Optineurin Defects Cause TDP43-Pathology with Autophagic Vacuolar Formation. Neurobiol. Dis. 2021;148:105215. doi: 10.1016/j.nbd.2020.105215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105215</ArticleId><ArticleId IdType="pubmed">33296728</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P. Acetylation-Induced TDP-43 Pathology Is Suppressed by an HSF1-Dependent Chaperone Program. Nat. Commun. 2017;8:82. doi: 10.1038/s41467-017-00088-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00088-4</ArticleId><ArticleId IdType="pmc">PMC5517419</ArticleId><ArticleId IdType="pubmed">28724966</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong Y.C., Holzbaur E.L.F. Optineurin Is an Autophagy Receptor for Damaged Mitochondria in Parkin-Mediated Mitophagy That Is Disrupted by an ALS-Linked Mutation. Cell Biol. 2014;111:4439&#x2013;4448. doi: 10.1073/pnas.1405752111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1405752111</ArticleId><ArticleId IdType="pmc">PMC4210283</ArticleId><ArticleId IdType="pubmed">25294927</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans C.S., Holzbaur E.L. Degradation of Engulfed Mitochondria Is Rate-Limiting in Optineurin-Mediated Mitophagy in Neurons. eLife. 2020;9:e50260. doi: 10.7554/eLife.50260.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.50260</ArticleId><ArticleId IdType="pmc">PMC6959996</ArticleId><ArticleId IdType="pubmed">31934852</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidib&#xe9; H., Khalfallah Y., Xiao S., G&#xf3;mez N.B., Fakim H., Tank E.M.H., Di Tomasso G., Bareke E., Aulas A., McKeever P.M., et al. TDP-43 Stabilizes G3BP1 MRNA: Relevance to Amyotrophic Lateral Sclerosis/Frontotemporal Dementia. Brain. 2021;144:3461&#x2013;3476. doi: 10.1093/brain/awab217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab217</ArticleId><ArticleId IdType="pmc">PMC8677511</ArticleId><ArticleId IdType="pubmed">34115105</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R.H., Phil D. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marchi F., Munitic I., Amedei A., Berry J.D., Feldman E.L., Aronica E., Nardo G., Van Weehaeghe D., Niccolai E., Prtenjaca N., et al. Interplay between Immunity and Amyotrophic Lateral Sclerosis: Clinical Impact. Neurosci. Biobehav. Rev. 2021;127:958&#x2013;978. doi: 10.1016/j.neubiorev.2021.06.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2021.06.027</ArticleId><ArticleId IdType="pmc">PMC8428677</ArticleId><ArticleId IdType="pubmed">34153344</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y., Ofengeim D., Najafov A., Das S., Saberi S., Li Y., Hitomi J., Zhu H., Chen H., Mayo L., et al. RIPK1 Mediates Axonal Degeneration by Promoting Inflammation and Necroptosis in ALS. Science. 2016;353:603&#x2013;608. doi: 10.1126/science.aaf6803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf6803</ArticleId><ArticleId IdType="pmc">PMC5444917</ArticleId><ArticleId IdType="pubmed">27493188</ArticleId></ArticleIdList></Reference><Reference><Citation>Root J., Merino P., Nuckols A., Johnson M., Kukar T. Lysosome Dysfunction as a Cause of Neurodegenerative Diseases: Lessons from Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neurobiol. Dis. 2021;154:105360. doi: 10.1016/j.nbd.2021.105360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2021.105360</ArticleId><ArticleId IdType="pmc">PMC8113138</ArticleId><ArticleId IdType="pubmed">33812000</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama Y., Tsuji K., Ayaki T., Mori M., Tokunaga F., Ito H. Linear Polyubiquitin Chain Modification of TDP-43-Positive Neuronal Cytoplasmic Inclusions in Amyotrophic Lateral Sclerosis. J. Neuropathol. Exp. Neurol. 2020;79:256&#x2013;265. doi: 10.1093/jnen/nlz135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlz135</ArticleId><ArticleId IdType="pubmed">31951008</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen W.-C., Li H.-Y., Chen G.-C., Chern Y., Tu P. Mutations in the Ubiquitin-Binding Domain of OPTN/Optineurin Interfere with Autophagy-Mediated Degradation of Misfolded Proteins by a Dominant-Negative Mechanism. Autophagy. 2015;11:685&#x2013;700. doi: 10.4161/auto.36098.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.36098</ArticleId><ArticleId IdType="pmc">PMC4502753</ArticleId><ArticleId IdType="pubmed">25484089</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Shao Z., Liu X., Hou M., Cheng F., Lei D., Yuan H. The E50K Optineurin Mutation Impacts Autophagy-Mediated Degradation of TDP-43 and Leads to RGC Apoptosis in Vivo and in Vitro. Cell Death Discov. 2021;7:49. doi: 10.1038/s41420-021-00432-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-021-00432-0</ArticleId><ArticleId IdType="pmc">PMC7960725</ArticleId><ArticleId IdType="pubmed">33723228</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S.-C., Albuquerque C.P., Han J.S., Lagier-Tourenne C., Tokunaga S., Zhou H., Cleveland D.W. ALS-Associated Mutations in TDP-43 Increase Its Stability and Promote TDP-43 Complexes with FUS/TLS. Proc. Natl. Acad. Sci. USA. 2010;107:13318&#x2013;13323. doi: 10.1073/pnas.1008227107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1008227107</ArticleId><ArticleId IdType="pmc">PMC2922163</ArticleId><ArticleId IdType="pubmed">20624952</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Advances in Genetics. Volume 91. Elsevier; Amsterdam, The Netherlands: 2015. Functional Significance of TDP-43 Mutations in Disease; pp. 1&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">26410029</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala Y.M., Zago P., D&#x2019;Ambrogio A., Xu Y.-F., Petrucelli L., Buratti E., Baralle F.E. Structural Determinants of the Cellular Localization and Shuttling of TDP-43. J. Cell Sci. 2008;121:3778&#x2013;3785. doi: 10.1242/jcs.038950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.038950</ArticleId><ArticleId IdType="pubmed">18957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M., Lagier-Tourenne C., Hutt K.R., Huelga S.C., Moran J., Liang T.Y., Ling S.-C., Sun E., Wancewicz E., Mazur C., et al. Long Pre-MRNA Depletion and RNA Missplicing Contribute to Neuronal Vulnerability from Loss of TDP-43. Nat. Neurosci. 2011;14:459&#x2013;468. doi: 10.1038/nn.2779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2779</ArticleId><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton C.F., Good S.K., Atkin S., Dewey C.M., Mayer P., Herz J., Yu G. TDP-43 Is a Developmentally Regulated Protein Essential for Early Embryonic Development. J. Biol. Chem. 2010;285:6826&#x2013;6834. doi: 10.1074/jbc.M109.061846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.061846</ArticleId><ArticleId IdType="pmc">PMC2825476</ArticleId><ArticleId IdType="pubmed">20040602</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakihana T., Takahashi M., Katsuragi Y., Yamashita S.-I., Sango J., Kanki T., Onodera O., Fujii M. The Optineurin/TIA1 Pathway Inhibits Aberrant Stress Granule Formation and Reduces Ubiquitinated TDP-43. iScience. 2021;24:102733. doi: 10.1016/j.isci.2021.102733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.102733</ArticleId><ArticleId IdType="pmc">PMC8259439</ArticleId><ArticleId IdType="pubmed">34258561</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco G., Lomartire A., Calvo A., Risso A., De Luca E., Mostert M., Mandrioli J., Caponnetto C., Borghero G., Manera U., et al. Monocytes of Patients with Amyotrophic Lateral Sclerosis Linked to Gene Mutations Display Altered TDP-43 Subcellular Distribution. Neuropathol. Appl. Neurobiol. 2017;43:133&#x2013;153. doi: 10.1111/nan.12328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12328</ArticleId><ArticleId IdType="pubmed">27178390</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes N., Nero L., Lyons S., Ivanov P., Mittelmeier T., Bolger T., Buchan J. Stress Granule Assembly Can Facilitate but Is Not Required for TDP-43 Cytoplasmic Aggregation. Biomolecules. 2020;10:1367. doi: 10.3390/biom10101367.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10101367</ArticleId><ArticleId IdType="pmc">PMC7650667</ArticleId><ArticleId IdType="pubmed">32992901</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>